{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,30]],"date-time":"2026-08-30T01:14:58Z","timestamp":1788052498483,"version":"build-2784847793"},"reference-count":40,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100007129","name":"Shandong Province Natural Science Foundation","doi-asserted-by":"publisher","award":["ZR2021QH303"],"award-info":[{"award-number":["ZR2021QH303"]}],"id":[{"id":"10.13039\/501100007129","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82304279"],"award-info":[{"award-number":["82304279"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82204665"],"award-info":[{"award-number":["82204665"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Medicinal Chemistry"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1016\/j.ejmech.2026.119211","type":"journal-article","created":{"date-parts":[[2026,8,8]],"date-time":"2026-08-08T15:07:20Z","timestamp":1786201640000},"page":"119211","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Discovery of a novel 1H-pyrazole-3-amine derivative 6h with potent antitumor activity by targeting tubulin and FLT3"],"prefix":"10.1016","volume":"318","author":[{"ORCID":"https:\/\/orcid.org\/0009-0006-0389-9949","authenticated-orcid":false,"given":"Bao-Kai","family":"Dou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-8497-256X","authenticated-orcid":false,"given":"Xiang-Yu","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao-Fen","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4609-966X","authenticated-orcid":false,"given":"Ying-Jie","family":"Cui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejmech.2026.119211_bib1","first-page":"151","article-title":"The regulatory effect of Tau protein on polymerization of MCF7 microtubules in vitro","volume":"17","author":"Feizabadi","year":"2019","journal-title":"Biochem. Biophys. Rep."},{"key":"10.1016\/j.ejmech.2026.119211_bib2","first-page":"2076","article-title":"The microtubule-targeted agent lisavanbulin (BAL101553) shows antitumor activity in lymphoma models","volume":"13","author":"Spriano","year":"2023","journal-title":"Am. J. Cancer Res."},{"key":"10.1016\/j.ejmech.2026.119211_bib3","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2024.117022","article-title":"Tubulin\/HDAC dual-target inhibitors: insights from design strategies, SARs, and therapeutic potential","volume":"281","author":"Zhang","year":"2025","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.119211_bib4","doi-asserted-by":"crossref","first-page":"2396","DOI":"10.1038\/s41467-025-57555-6","article-title":"Hydrolysis-deficient mosaic microtubules as faithful mimics of the GTP cap","volume":"16","author":"Estevez-Gallego","year":"2025","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ejmech.2026.119211_bib5","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1007\/978-3-031-58311-7_3","article-title":"The impact of centrosome pathologies on ovarian cancer development and progression with a focus on centrosomes as therapeutic target","volume":"1452","author":"Schatten","year":"2024","journal-title":"Adv. Exp. Med. Biol."},{"key":"10.1016\/j.ejmech.2026.119211_bib6","doi-asserted-by":"crossref","first-page":"8650","DOI":"10.1021\/acs.jmedchem.5c02701","article-title":"Tubulin zone occupancy by PDB-deposited colchicine binding site inhibitors","volume":"69","author":"Colorado-Pablo","year":"2026","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.119211_bib7","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1016\/j.tcb.2018.05.001","article-title":"Microtubule-targeting agents: strategies to hijack the cytoskeleton","volume":"28","author":"Steinmetz","year":"2018","journal-title":"Trends Cell Biol."},{"key":"10.1016\/j.ejmech.2026.119211_bib8","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmcl.2025.130167","article-title":"Recent developments of benzimidazole based analogs as potential tubulin polymerization inhibitors: a critical review","volume":"122","author":"Reddyrajula","year":"2025","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.ejmech.2026.119211_bib9","doi-asserted-by":"crossref","DOI":"10.1016\/j.taap.2022.115883","article-title":"Novel microtubule inhibitor SQ overcomes multidrug resistance in MCF-7\/ADR cells by inhibiting BCRP function and mediating apoptosis","volume":"436","author":"Chang","year":"2022","journal-title":"Toxicol. Appl. Pharmacol."},{"key":"10.1016\/j.ejmech.2026.119211_bib10","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2024.107310","article-title":"Design and synthesis of novel imidazole-chalcone derivatives as microtubule protein polymerization inhibitors to treat cervical cancer and reverse cisplatin resistance","volume":"147","author":"Liu","year":"2024","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.ejmech.2026.119211_bib11","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2024.1425617","article-title":"Ocular adverse events associated with antibody-drug conjugates in oncology: a pharmacovigilance study based on FDA adverse event reporting system (FAERS)","volume":"15","author":"Mao","year":"2024","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.ejmech.2026.119211_bib12","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1021\/acs.jnatprod.2c00106","article-title":"Utilization of photoaffinity labeling to investigate binding of microtubule stabilizing agents to P-glycoprotein and beta-tubulin","volume":"85","author":"Huang Yang","year":"2022","journal-title":"J. Nat. Prod."},{"key":"10.1016\/j.ejmech.2026.119211_bib13","doi-asserted-by":"crossref","first-page":"785","DOI":"10.4155\/fmc-2021-0124","article-title":"Structural insight into SSE15206 in complex with tubulin provides a rational design for pyrazolinethioamides as tubulin polymerization inhibitors","volume":"14","author":"Ma","year":"2022","journal-title":"Future Med. Chem."},{"key":"10.1016\/j.ejmech.2026.119211_bib14","doi-asserted-by":"crossref","first-page":"55","DOI":"10.4161\/jkst.20006","article-title":"STAT signaling in the pathogenesis and treatment of myeloid malignancies","volume":"1","author":"Bar-Natan","year":"2012","journal-title":"JAK-STAT"},{"key":"10.1016\/j.ejmech.2026.119211_bib15","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1093\/neuonc\/noq003","article-title":"Analysis of receptor tyrosine kinases (RTKs) and downstream pathways in chordomas","volume":"12","author":"Tamborini","year":"2010","journal-title":"Neuro Oncol."},{"key":"10.1016\/j.ejmech.2026.119211_bib16","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.1152\/physrev.00029.2018","article-title":"FMS-like tyrosine kinase 3\/FLT3: from basic science to clinical implications","volume":"99","author":"Kazi","year":"2019","journal-title":"Physiol. Rev."},{"key":"10.1016\/j.ejmech.2026.119211_bib17","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/1756-8722-4-13","article-title":"Downstream molecular pathways of FLT3 in the pathogenesis of acute myeloid leukemia: biology and therapeutic implications","volume":"4","author":"Takahashi","year":"2011","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.ejmech.2026.119211_bib18","article-title":"Mutations of FLT3 receptor affect its surface glycosylation, intracellular localization, and downstream signaling","volume":"13","author":"Takahashi","year":"2020","journal-title":"Leuk. Res. Rep."},{"key":"10.1016\/j.ejmech.2026.119211_bib19","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1039\/D2MD00067A","article-title":"FLT3 inhibitors for acute myeloid leukemia: successes, defeats, and emerging paradigms","volume":"13","author":"Acharya","year":"2022","journal-title":"RSC Med. Chem."},{"key":"10.1016\/j.ejmech.2026.119211_bib20","doi-asserted-by":"crossref","DOI":"10.1038\/srep11702","article-title":"Homology modeling of DFG-in FMS-like tyrosine kinase 3 (FLT3) and structure-based virtual screening for inhibitor identification","volume":"5","author":"Ke","year":"2015","journal-title":"Sci. Rep."},{"key":"10.1016\/j.ejmech.2026.119211_bib21","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.03445","article-title":"Overcoming myelosuppression due to synthetic lethal toxicity for FLT3-targeted acute myeloid leukemia therapy","volume":"3","author":"Warkentin","year":"2014","journal-title":"eLife"},{"key":"10.1016\/j.ejmech.2026.119211_bib22","article-title":"Recurrence of the oxazole motif in tubulin colchicine site inhibitors with anti-tumor activity","volume":"1","author":"Barreca","year":"2021","journal-title":"Eur. J. Med. Chem. Rep"},{"key":"10.1016\/j.ejmech.2026.119211_bib23","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2019.111968","article-title":"The discovery of novel indazole derivatives as tubulin colchicine site binding agents that displayed potent antitumor activity both in vitro and in vivo","volume":"187","author":"Cui","year":"2020","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.119211_bib24","doi-asserted-by":"crossref","first-page":"3239","DOI":"10.1002\/cncr.35423","article-title":"Top advances of the year: targeted therapy for lung cancer","volume":"130","author":"Makarem","year":"2024","journal-title":"Cancer"},{"key":"10.1016\/j.ejmech.2026.119211_bib25","doi-asserted-by":"crossref","first-page":"8881","DOI":"10.1021\/acs.jmedchem.9b00017","article-title":"Rational design of multitarget-directed ligands: strategies and emerging paradigms","volume":"62","author":"Zhou","year":"2019","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.119211_bib26","doi-asserted-by":"crossref","first-page":"10581","DOI":"10.1021\/acs.jmedchem.1c00683","article-title":"Rational multitargeted drug design strategy from the perspective of a medicinal chemist","volume":"64","author":"Li","year":"2021","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.119211_bib27","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2023.115687","article-title":"Design, synthesis, and biological evaluation of 3, 5-disubsituted-1H-pyrazolo[3,4-b]pyridines as multiacting inhibitors against microtubule and kinases","volume":"259","author":"Ning","year":"2023","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.119211_bib28","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2024.116543","article-title":"Dual-target inhibitors of colchicine binding site for cancer treatment","volume":"274","author":"Lu","year":"2024","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.119211_bib29","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2017.02.030","article-title":"Phase II trial of the PI3 kinase inhibitor buparlisib (BKM-120) with or without enzalutamide in men with metastatic castration resistant prostate cancer","volume":"81","author":"Armstrong","year":"2017","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.ejmech.2026.119211_bib30","doi-asserted-by":"crossref","DOI":"10.1038\/ncomms14683","article-title":"Deconvolution of Buparlisib's mechanism of action defines specific PI3K and tubulin inhibitors for therapeutic intervention","volume":"8","author":"Bohnacker","year":"2017","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ejmech.2026.119211_bib31","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/j.molcel.2017.09.012","article-title":"Combined CRISPRi\/a-based chemical genetic screens reveal that rigosertib is a microtubule-destabilizing agent","volume":"68","author":"Jost","year":"2017","journal-title":"Mol. Cell"},{"key":"10.1016\/j.ejmech.2026.119211_bib32","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.3390\/pharmaceutics15041232","article-title":"Lights and shadows on the cancer multi-target inhibitor Rigosertib (ON-01910.Na)","volume":"15","author":"Monfort-Vengut","year":"2023","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.ejmech.2026.119211_bib33","first-page":"181","article-title":"Tivantinib in MET-high hepatocellular carcinoma patients and the ongoing phase III clinical trial, Hepat","volume":"1","author":"Rimassa","year":"2014","journal-title":"Oncologist"},{"key":"10.1016\/j.ejmech.2026.119211_bib34","doi-asserted-by":"crossref","first-page":"2978","DOI":"10.1158\/1535-7163.MCT-14-0462","article-title":"Tivantinib (ARQ 197) exhibits antitumor activity by directly interacting with tubulin and overcomes ABC transporter-mediated drug resistance","volume":"13","author":"Aoyama","year":"2014","journal-title":"Mol. Cancer Therapeut."},{"key":"10.1016\/j.ejmech.2026.119211_bib35","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmcl.2023.129494","article-title":"Benzimidazole derivatives as tubulin polymerization inhibitors: design, synthesis and in vitro cytotoxicity studies","volume":"96","author":"Laxmikeshav","year":"2023","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.ejmech.2026.119211_bib36","doi-asserted-by":"crossref","first-page":"7197","DOI":"10.1021\/acs.jmedchem.4c00051","article-title":"Discovery of a novel orally bioavailable FLT3-PROTAC degrader for efficient treatment of acute myeloid leukemia and overcoming resistance of FLT3 inhibitors","volume":"67","author":"Wang","year":"2024","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.119211_bib37","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1158\/1535-7163.MCT-25-0559","article-title":"PM534, a novel colchicine-site tubulin inhibitor with broad-spectrum and resistance-overcoming antitumor activity","volume":"25","author":"Aviles","year":"2026","journal-title":"Mol. Cancer Therapeut."},{"key":"10.1016\/j.ejmech.2026.119211_bib38","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2020.112205","article-title":"Discovery of orally active indirubin-3'-oxime derivatives as potent type 1 FLT3 inhibitors for acute myeloid leukemia","volume":"195","author":"Jeong","year":"2020","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.119211_bib39","doi-asserted-by":"crossref","first-page":"229","DOI":"10.3892\/mmr.2024.13353","article-title":"In silico and in vitro study of FLT3 inhibitors and their application in acute myeloid leukemia","volume":"30","author":"Carranza-Aranda","year":"2024","journal-title":"Mol. Med. Rep."},{"key":"10.1016\/j.ejmech.2026.119211_bib40","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2023.115870","article-title":"The discovery of water-soluble indazole derivatives as potent microtubule polymerization inhibitors","volume":"262","author":"Cui","year":"2023","journal-title":"Eur. J. Med. Chem."}],"container-title":["European Journal of Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523426006562?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523426006562?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,30]],"date-time":"2026-08-30T00:19:33Z","timestamp":1788049173000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0223523426006562"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,11]]},"references-count":40,"alternative-id":["S0223523426006562"],"URL":"https:\/\/doi.org\/10.1016\/j.ejmech.2026.119211","relation":{},"ISSN":["0223-5234"],"issn-type":[{"value":"0223-5234","type":"print"}],"subject":[],"published":{"date-parts":[[2026,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Discovery of a novel 1H-pyrazole-3-amine derivative 6h with potent antitumor activity by targeting tubulin and FLT3","name":"articletitle","label":"Article Title"},{"value":"European Journal of Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejmech.2026.119211","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Masson SAS. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"119211"}}